Siyi Chen

Siyi Chen

Auto-generated profile, based on publicly available information

Siyi Chen

University of Michigan School of Medicine 1 Division of Hematology-Oncology, Department of Internal Medicine Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
JBJohanna M. Buschhaus
Johanna M. Buschhaus
SRShrila Rajendran
Shrila Rajendran
SCSiyi Chen
Siyi Chen
BWBryan L. Wharram
Bryan L. Wharram
ABAvinash S. Bevoor
Avinash S. Bevoor
GLGary Luker
Gary Luker
Cancer cells reprogram energy metabolism through metabolic plasticity, adapting ATP-generating pathways in response to treatment or microenvironmental changes. Such adaptations enable cancer cells to resist standard therapy. We employed a coculture model of estrogen receptor–positive (ER+) breast cancer and mesenchymal stem cells (MSC) to model interactions of cancer cells with stromal microenvironments. Using single-cell endogenous and engineered biosensors for cellular metabolism, coculture with MSCs increased oxidative phosphorylation, intracellular ATP, and resistance of cancer cells to standard therapies. Cocultured cancer cells had increased MCT4, a lactate transporter, and were sensitive to the MCT1/4 inhibitor syrosingopine. Combining syrosingopine with fulvestrant, a selective estrogen receptor degrading drug, overcame resistance of ER+ breast cancer cells in coculture with MSCs. Treatment with antiestrogenic therapy increased metabolic plasticity and maintained intracellular ATP levels, while MCT1/4 inhibition successfully limited metabolic transitions and decreased ATP levels. Furthermore, MCT1/4 inhibition decreased heterogenous metabolic treatment responses versus antiestrogenic therapy. These data establish MSCs as a mediator of cancer cell metabolic plasticity and suggest metabolic interventions as a promising strategy to treat ER+ breast cancer and overcome resistance to standard clinical therapies. Implications: This study reveals how MSCs reprogram metabolism of ER+ breast cancer cells and point to MCT4 as potential therapeutic target to overcome resistance to antiestrogen drugs. Watch the interview with Gary D. Luker, MD, recipient of the 2025 Molecular Cancer Research Award for Outstanding Journal Article: https://vimeo.com/1100470714

19 February 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
QWQing Wang
Qing Wang
Francesco BoccalatteFrancesco Boccalatte
Francesco Boccalatte
JXJason Xu
Jason Xu
GGGiovanni Gambi
Giovanni Gambi
BNBettina Nadorp
Bettina Nadorp
MCMark Y. Chiang
Mark Y. Chiang
While the mutational landscape across early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) and ETP-like leukemia is known, establishing a unified framework that activates stem cell genes characteristic of these tumors remains elusive. Using complementary mouse and human models, chromatin mapping, and enhancer profiling, we show that the coactivator ZMIZ1 promotes normal and malignant ETP population growth by inducing the transcription factor MYB in feedforward circuits to convergently activate oncogenes (MEF2C, MYCN, and BCL2) through essential enhancers. A key superenhancer, the N-Myc regulating enhancer (NMRE), drives malignant ETP population growth but is dispensable for normal lymphopoiesis. This network of stem cell superenhancers identifies treatment-resistant tumors and poor survival outcomes; unifies diverse ETP-ALLs; and contributes to cardinal features of the recently genomically identified high-risk bone marrow progenitor-like (BMP-like) ETP-ALL tumor—stem cell/myeloid gene expression, inhibited NOTCH1-induced T-cell development, aggressive clinical behavior, and venetoclax sensitivity. Since ZMIZ1 is dispensable for essential homeostasis, it might be possible to safely target this network to treat high-risk diseases.

26 September 2022 in Scientia Horticulturae
Verified
Journal Article
Closed access
JGJian Gao
Jian Gao
ZZZhangfei Zheng
Zhangfei Zheng
SCSiyi Chen
Siyi Chen
Chuanyi WangChuanyi Wang
Chuanyi Wang
FCFa-Bo Chen
Fa-Bo Chen
WLWenbo Li
Wenbo Li

22 July 2025
Verified
Other
Open access
JBJohanna M. Buschhaus
Johanna M. Buschhaus
SRShrila Rajendran
Shrila Rajendran
SCSiyi Chen
Siyi Chen
BWBryan L. Wharram
Bryan L. Wharram
ABAvinash S. Bevoor
Avinash S. Bevoor
GLGary Luker
Gary Luker
Cancer cells reprogram energy metabolism through metabolic plasticity, adapting ATP-generating pathways in response to treatment or microenvironmental changes. Such adaptations enable cancer cells to resist standard therapy. We employed a coculture model of estrogen receptor–positive (ER+) breast cancer and mesenchymal stem cells (MSC) to model interactions of cancer cells with stromal microenvironments. Using single-cell endogenous and engineered biosensors for cellular metabolism, coculture with MSCs increased oxidative phosphorylation, intracellular ATP, and resistance of cancer cells to standard therapies. Cocultured cancer cells had increased MCT4, a lactate transporter, and were sensitive to the MCT1/4 inhibitor syrosingopine. Combining syrosingopine with fulvestrant, a selective estrogen receptor degrading drug, overcame resistance of ER+ breast cancer cells in coculture with MSCs. Treatment with antiestrogenic therapy increased metabolic plasticity and maintained intracellular ATP levels, while MCT1/4 inhibition successfully limited metabolic transitions and decreased ATP levels. Furthermore, MCT1/4 inhibition decreased heterogenous metabolic treatment responses versus antiestrogenic therapy. These data establish MSCs as a mediator of cancer cell metabolic plasticity and suggest metabolic interventions as a promising strategy to treat ER+ breast cancer and overcome resistance to standard clinical therapies.Implications:This study reveals how MSCs reprogram metabolism of ER+ breast cancer cells and point to MCT4 as potential therapeutic target to overcome resistance to antiestrogen drugs.Watch the interview with Gary D. Luker, MD, recipient of the 2025 Molecular Cancer Research Award for Outstanding Journal Article: https://vimeo.com/1100470714

3 April 2023
Verified
Other
Open access
JBJohanna M. Buschhaus
Johanna M. Buschhaus
SRShrila Rajendran
Shrila Rajendran
SCSiyi Chen
Siyi Chen
BWBryan L. Wharram
Bryan L. Wharram
ABAvinash S. Bevoor
Avinash S. Bevoor
GLGary Luker
Gary Luker
Figure S1. Representative images of NADH lifetimes for various experimental conditions. Cell type of interest is bolded in co-culture comparisons. Top row of images denotes cancer cells marked with nuclear mCherry. Pseudocolor scale depicts high (red) and low (blue) NADH lifetime. Scale bar = 50 µm. A) HS5 and HS27a MSCs in monoculture. B-C) MCF7 (B) or T47D (C) cells in monoculture or with conditioned media (CM) from listed MSCs. D) HCC1428 (HCC) cancer cells in monoculture, CM from MSCs, or direct co-culture with MSCs.

3 April 2023
Verified
Other
Open access
JBJohanna M. Buschhaus
Johanna M. Buschhaus
SRShrila Rajendran
Shrila Rajendran
SCSiyi Chen
Siyi Chen
BWBryan L. Wharram
Bryan L. Wharram
ABAvinash S. Bevoor
Avinash S. Bevoor
GLGary Luker
Gary Luker
Figure S2. NADH lifetime and ROS quantification for ER+ breast cancer cells with CM and MSCs in monoculture and co-culture. Cell type of interest is bolded in co-culture comparisons. A-B) Histograms of NADH lifetime for HS5 (A) and HS27a (B) in monoculture or co-culture with MCF7, T47D, and HCC1428 (HCC) ER+ breast cancer cells. C-E) Histograms of NADH lifetime for MCF7 (C), T47D (D), and HCC1428 (HCC, E) cells in co-culture and monoculture with control or CM from HS5 or HS27a MSCs. Dashed lines represent cancer cells in CM and solid lines represent cancer cells in monoculture or co-culture with MSCs. N>100 cells.